<DOC>
	<DOCNO>NCT01449370</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) and/or optimal biologic dose ( OBD ) , safety tolerability , dose-limiting toxicity ( DLT ) TAK-117 administer orally subject advance solid malignancy .</brief_summary>
	<brief_title>Dose Escalation Study TAK-117 ( MLN1117 ) Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Subjects PIK3CA gene mutation status assess prior enrol study Subjects must document disease progression prior enrol study locally advance metastatic solid tumor exception primary brain tumor , fail eligible standard care therapy . Age great equal ( &gt; = ) 18 year , include male female ; Eastern cooperative oncology group ( ECOG ) performance status ( PS ) 01 ; Adequate organ function ; Male subject must surgically sterile must agree use physicianapproved contraception study 30 day follow last study drug administration ; Ability swallow oral medication ; Ability understand willingness sign inform consent prior initiation study procedure ; For woman childbearing potential , negative serum pregnancy test within 14 day prior first study drug administration use physicianapproved method birth control 30 day prior first study drug administration 30 day follow last study drug administration Diagnosis primary brain tumor ; untreated brain metastasis history leptomeningeal disease spinal cord compression ; Received prior cancer investigational therapy within 2 week prior first administration study drug ; Have receive systemic corticosteroid within one week prior first administration study drug ; Clinically significant cardiac disease ; Myocardial infarction unstable angina within 6 month prior first administration study drug ; Malabsorption ; Poorly control diabetes mellitus ; Pregnancy ( positive serum urine pregnancy test ) breast feeding ; Untreated brain metastasis history leptomeningeal disease spinal cord compression ; Failed recover reversible effect prior anticancer therapy ; Have receive selective phosphoinositide3kinase alpha isoform ( PI3Kalpha ) inhibitor Other clinically significant comorbidities , uncontrolled pulmonary disease , active central nervous system ( CNS ) disease , active infection , condition could compromise subject 's participation study Known human immunodeficiency virus ( HIV ) infection Have secondary malignancy within last 3 year prior first dose study drug , exclude treat nonmelanoma skin cancer , carcinoma situ , locallytreated prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>INK1117</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>KINASE</keyword>
	<keyword>TUMOR</keyword>
	<keyword>CANCER</keyword>
	<keyword>Locally advanced metastatic solid tumor</keyword>
	<keyword>eligible standard care therapy</keyword>
</DOC>